Details for New Drug Application (NDA): 209290
✉ Email this page to a colleague
NDA 209290 describes ALCAFTADINE, which is a drug marketed by Alembic, Eugia Pharma, and Gland Pharma Ltd, and is included in three NDAs. It is available from three suppliers. Additional details are available on the ALCAFTADINE profile page.
The generic ingredient in ALCAFTADINE is alcaftadine. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.
The generic ingredient in ALCAFTADINE is alcaftadine. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.
Summary for 209290
| Tradename: | ALCAFTADINE |
| Applicant: | Alembic |
| Ingredient: | alcaftadine |
| Patents: | 0 |
Pharmacology for NDA: 209290
| Mechanism of Action | Histamine H1 Receptor Antagonists |
Suppliers and Packaging for NDA: 209290
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ALCAFTADINE | alcaftadine | SOLUTION/DROPS;OPHTHALMIC | 209290 | ANDA | Alembic Pharmaceuticals Inc. | 62332-147 | 62332-147-03 | 1 BOTTLE in 1 CARTON (62332-147-03) / 3 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | OTC | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.25% | ||||
| Approval Date: | Oct 2, 2024 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
